home / stock / apli:cc / apli:cc quote
Last: | $0.07 |
---|---|
Change Percent: | 0.0% |
Open: | $0.07 |
Close: | $0.07 |
High: | $0.07 |
Low: | $0.0675 |
Volume: | 87,908 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.07 | $0.07 | $0.07 | $0.07 | $0.0675 | 87,908 | 08-02-2022 |
$0.1 | $0.1 | $0.1 | $0.105 | $0.1 | 675,643 | 05-06-2022 |
$0.105 | $0.105 | $0.105 | $0.105 | $0.095 | 1,283,284 | 05-05-2022 |
$0.1 | $0.1 | $0.1 | $0.105 | $0.1 | 79,694 | 05-04-2022 |
$0.105 | $0.11 | $0.105 | $0.11 | $0.1 | 186,873 | 05-03-2022 |
$0.105 | $0.105 | $0.105 | $0.105 | $0.105 | 27,622 | 05-02-2022 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.105 | 53,688 | 04-29-2022 |
$0.11 | $0.105 | $0.11 | $0.11 | $0.105 | 24,601 | 04-28-2022 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.105 | 81,075 | 04-27-2022 |
$0.11 | $0.105 | $0.11 | $0.11 | $0.105 | 78,372 | 04-26-2022 |
$0.11 | $0.11 | $0.11 | $0.11 | $0.11 | 94,229 | 04-25-2022 |
$0.11 | $0.115 | $0.11 | $0.115 | $0.11 | 286,893 | 04-22-2022 |
$0.115 | $0.115 | $0.115 | $0.115 | $0.11 | 40,222 | 04-21-2022 |
$0.11 | $0.115 | $0.11 | $0.12 | $0.11 | 74,533 | 04-20-2022 |
$0.115 | $0.115 | $0.115 | $0.115 | $0.11 | 30,497 | 04-19-2022 |
$0.115 | $0.11 | $0.115 | $0.12 | $0.11 | 150,906 | 04-18-2022 |
$0.115 | $0.12 | $0.115 | $0.12 | $0.11 | 99,529 | 04-15-2022 |
$0.115 | $0.12 | $0.115 | $0.12 | $0.11 | 99,262 | 04-14-2022 |
$0.12 | $0.115 | $0.12 | $0.12 | $0.11 | 208,864 | 04-13-2022 |
$0.12 | $0.115 | $0.12 | $0.12 | $0.11 | 187,230 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc. Company Name:
APLI:CC Stock Symbol:
TSXC Market:
Appili Therapeutics Inc. Website:
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 ...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...